ADVERTISEMENT

Transitions Magazine

Transitions is published bi-monthly for members of the APhA New Practitioner Network. The online newsletter contains information focused on life inside and outside pharmacy practice, providing guidance on various areas of professional, personal, and practice development. Each issue includes in-depth articles on such topics as personal financial management, innovative practice sites, career profiles, career development tools, residency and postgraduate programs, and more.

Dr Marie Sartain
/ Categories: APhA News

Almost one-half of Americans would spend $100 a month for weight loss drugs

Nearly one-half of Americans said they would be willing to spend up to $100 a month for new weight loss medicines such as semaglutide (Wegovy—Novo Nordisk), and one-third said they would indefinitely pay whatever they can afford to get the drugs, according to a new survey by STAT and Harris Poll.

Demand is so great for the drugs, known as GLP-1 receptor agonists, that nearly one-quarter said they would pay up to $250 each month, with another 17% expressing a willingness to spend as much as $500 each month.

However, 84% believe insurance companies should cover the injectable medicines, which carry list prices ranging from $900 to $1,300 a month. Fewer than 25% of employers cover the medications, according to a 2022 survey of more than 500 employers.

The findings arrive as the medications have become a controversial sensation thanks to studies showing they can help people lose significant weight without causing notable adverse effects.

Nearly two-thirds of those surveyed indicated they would pursue one of the medicines to help improve their physical health, while 51% cited their self-image as a reason to do so.

Print
12026 Rate this article:
5.0
Please login or register to post comments.
Advertisement
Advertisement
Advertisement
Advertisement

ADVERTISEMENT